Novel Drug, First Tx for Rare Uveal Melanoma
A novel drug, the first in its class, is also the first treatment approved for use in uveal melanoma, a rare cancer of the eye, after it was shown to improve overall survival.
Source: medscape.com
📰 Project Orbis News
Page 10 - Project Orbis News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Project Orbis. Real-time updates on events, politics, business and more.
FDA Approves Immunocore's T-Cell Receptor Therapy Kimmtrak for Uveal Melanoma Patients
The drug is the first TCR therapy approved in the US for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Source: precisiononcologynews.com
Patients to receive new cancer drugs faster under Brexit rules shake-up
Seven medicines already approved as changes cut as much as a month off approval times
United Kingdom Dave Fredrickson Richard Sullivan Institute For Cancer European Medicines Agency European Commission
Source: telegraph.co.uk
Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Enhertu granted Priority Review for breast cancer
Investegate announcements from AstraZeneca PLC, Enhertu granted Priority Review for breast cancer
Source: investegate.co.uk
Enhertu granted Priority Review in US for patients with HER2-positive metastatic breast cancer treated with prior anti-HER2-based
AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu
Ken Takeshita Daiichi Sankyo Susan Galbraith Drug Administration European Society For Medical Oncology Biologics License Application
Source: miragenews.com
AstraZeneca receives priority review for breast cancer drug in US | 17 January 2022
AstraZeneca receives priority review for breast cancer drug in US
Source: stockmarketwire.com
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
U.S. Food and Drug Administration Approves Orencia (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...
15.12.2021 - Bristol Myers Squibb (NYSE:BMY): U.S. Food and Drug Administration Approves Orencia (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD) in Patients Undergoing ...
Source: wallstreet-online.de
FDA Approves First Drug to Prevent Graft Versus Host Disease
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Orencia (abatacept) for the prophylaxis (prevention) of acute graft versus host disease...
Richard Pazdur Bristol Myers Squibb Chanapa Tantibanchachai Oncology Center Marrow Transplant Research Drug Administration
Source: prnewswire.com